Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Eriksson, Jan W., Lundkvist, Per, Jansson, Per-Anders, Johansson, Lars, Kvarnström, Mats, Moris, Linda, Miliotis, Tasso, Forsberg, Gun-Britt, Risérus, Ulf, Lind, Lars, Oscarsson, Jan·2018·Diabetologia
DOI 10.1007/s00125-018-4675-2

Cited by (396)

Items 201–300 of 396

  1. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes
    Mohammad Shafi Kuchay, Narendra Singh Choudhary, Sunil Kumar Mishra, Anoop Misra · 2020 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  2. Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling
    Takayoshi Suga, Ken Sato, Tatsuya Ohyama, Sho Matsui, Takeshi Kobayashi, Hiroki Tojima, Norio Horiguchi, Yuichi Yamazaki, Satoru Kakizaki, Ayaka Nishikido et al. · 2020 · World Journal of Hepatology
  3. Therapeutic approaches for non-alcoholic steatohepatitis
    Luc F. Van Gaal, Jonathan Mertens, Sven Francque, Christophe E.M. De Block · 2021 · Therapeutic Advances in Endocrinology and Metabolism
  4. Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
    Reeju Amatya, Dong-Hee Lee, Kyoung Ah Min, Meong Cheol Shin · 2023 · Pharmaceutics
  5. Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
    Sunetra Mondal, Subhodip Pramanik, Vibhu Ranjan Khare, Cornelius James Fernandez, Joseph M Pappachan · 2024 · World Journal of Cardiology
  6. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Tarique Aziz, Mukesh Kumar Niraj, Shishir Kumar, Rajendra Kumar, Hina Parveen · 2024 · Cureus
  7. Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial
    Mona S. Abdel Monem, Abdulmoneim Adel, Maggie Abbassi, Doaa Hamed Abdelaziz, Mohamed Hassany, Maissa El Raziky, Nirmeen Ahmed Sabry · 2025 · Clinics and Research in Hepatology and Gastroenterology
  8. Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients
    Lucas Ribeiro dos Santos, Ricardo Baer Filho · 2020 · Metabolism Open
  9. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
    Mohammad Said Ramadan, Vincenzo Russo, Gerardo Nigro, Emanuele Durante‐Mangoni, Rosa Zampino · 2021 · Journal of Clinical Medicine
  10. Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?
    Matilda Florentin, Michael S. Kostapanos, Panagiotis G. Anagnostis, George L. Liamis · 2019 · Expert Opinion on Pharmacotherapy
  11. Nonalcoholic fatty liver disease
    Evangelia S. Makri, Stergios A. Pοlyzos · 2022 · Journal of Atherosclerosis Prevention and Treatment
  12. Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
    Konstantinos Malandris, Stylianos Papandreou, Ioannis Avgerinos, Thomas Karagiannis, Paschalis Paschos, Theodoros Michailidis, Aris Liakos, Eleni Bekiari, Emmanouil Sinakos, Απόστολος Τσάπας · 2023 · HORMONES
  13. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
    Paolo Raggi, Jovana Milić, Marcella Manicardi, Felice Cinque, Mark G. Swain, Giada Sebastiani, Giovanni Guaraldi · 2024 · Atherosclerosis
  14. Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes
    Xiuying Gao, Chuanming Zhu, Wei Ming Zhu, Lin Wang · 2024 · Biomedical Reports
  15. NAFLD/NASH and Diabetes
    Kavita Garg, SCOTT J. BRACKETT, Irl B. Hirsch, Satish K. Garg · 2020 · Diabetes Technology & Therapeutics
  16. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes
    Koichi Yabiku, Keiko Nakamoto, Maho Tsubakimoto · 2020 · Journal of Diabetes Research
  17. Effect of GLP-1 RA and SGLT2I on Biomarkers of Oxidative Stress in T2DM: A Systematic Review and Meta-analysis
    Huannan Wei, Lingyu Ye, Mingli Li, Shengzhu Huang, Zengnan Mo · 2025 · Journal of the Endocrine Society
  18. Effect of SGLT2 Inhibitors and Metformin on Inflammatory and Prognostic Biomarkers in Type 2 Diabetes Patients
    Yang Cao, Ning Liang, Ting Liu, Jingai Fang, Xiaodong Zhang · 2022 · Endocrine Metabolic & Immune Disorders - Drug Targets
  19. The effects of ω−3 fatty acids on inflammatory and oxidative stress markers in patients with Type 2 diabetes mellitus: A systematic review and meta-analysis of controlled trials
    Khursheed Muzammil, Abdulrahman Qais Khaleel, Muna Salih Merza, Ashishkumar Kyada, Indang Ariati Ariffin, Seema Verma, Harpreet Kaur, Shirn Hasaanzadeh · 2024 · Prostaglandins & Other Lipid Mediators
  20. Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions
    Anastasia Ntikoudi, Anastasia Papachristou, Afroditi Tsalkitzi, Nikoletta Margari, Eleni Evangelou, Eugenia D. Vlachou · 2025 · Diabetology
  21. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
    Changlun Hu, Tianhua Qu, Li Lin, Yi Huang, Huabao Liu, Chunyan Rao · 2023 · African Health Sciences
  22. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
    Amr Dokmak, Mohammad Almeqdadi, Hirsh D. Trivedi, Sandeep Krishnan · 2019 · World Journal of Hepatology
  23. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
    Elizabeth Mary Lamos, Megan Marie Kristan, Maka Siamashvili, Stephen N. Davis · 2021 · Expert Review of Clinical Pharmacology
  24. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis
    Mohammad Shafi Kuchay, Anoop Misra · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  25. Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials
    Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong · 2024 · Obesity Reviews
  26. Dapagliflozin Therapy Curative Effect Observation on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Chen Hu, YU CHUAN . WANG, Yu Xi, XIN MING. YAO · 2020 · Indian Journal of Pharmaceutical Sciences
  27. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Yang Wang, Ning Xia · 2022 · Hormone and Metabolic Research
  28. Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
    Gea Ciccarelli, Gianfranco Di Giuseppe, Francesca Cinti, Simona Moffa, Teresa Mezza, Andrea Giaccari · 2023 · Diabetes/Metabolism Research and Reviews
  29. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
    Anastasia Kontana, Κωνσταντίνος Τζιόμαλος · 2019 · World Journal of Gastroenterology
  30. Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?
    André Jacques Scheen · 2018 · Annals of Translational Medicine
  31. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitors response
    Bo Xu, Shaoqian Li, Bo Kang, Shangzhi Fan, Canyu Chen, Weiyi Li, Jixiang Chen, Zunbo He, Fan Tang, Jiecan Zhou · 2023 · Molecular Biology Reports
  32. Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
    Vanishri Ganakumar, Tejaswi Halebidu, Manjunath Goroshi, Vikrant Ghatnatti · 2024 · International journal of clinical metabolism and diabetes.
  33. Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and β-cell function in type 2 diabetes: A meta-analysis
    Shangyu Chai, Ruya Zhang, Zhiyuan Ning, Yi-man Zheng, Swapnil N. Rajpathak, Linong Ji · 2025 · World Journal of Diabetes
  34. Empagliflozin is more Effective in Reducing Microalbuminuria and alt Levels Compared with Dapagliflozin: Real Life Experience
    Hatice Gizem Günhan · 2020 · Acta Endocrinologica (Bucharest)
  35. Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,,
    Caiyan Zou, Yan Sun, Jun Liang · 2022 · Clinics and Research in Hepatology and Gastroenterology
  36. Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
    Farah Khaznadar, Ana Petrovic, Omar Khaznadar, Hrvoje Roguljić, Kristina Bojanić, Lucija Kuna, Stjepan Siber, Robert Smolić, Ines Bilić-Čurčić, George Y. Wu et al. · 2023 · Journal of Clinical Medicine
  37. Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease
    José Ignacio Martínez‐Montoro, Isabel María Cornejo-Pareja, Ana María Gómez‐Pérez, Francisco José Tinahones · 2021 · Nutrients
  38. Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis
    Ren, Qiao, Tan, Yao, Zhang, Guixiang, Dai, Yuzhao, Yang, Lidan, Wu, Yunmo, He, He, Chen, Jie · 2025 · Journal of Evidence-Based Medicine
  39. Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis
    Waseem Amjad, Adnan Malik, Waqas Qureshi, Brittany Burns Dennis, Mirrah Mumtaz, Rabbia Haider, Shakeel Muhammad Jamal, Faisal Jaura, Aijaz Ahmed · 2022 · Gastroenterology Review
  40. Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
    Qing Feng, Moya Wu, Zizhao Mai · 2025 · Frontiers in Cardiovascular Medicine
  41. Liver function effects of SGLT2 inhibitor and GLP ‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
    Daisuke Tsuriya, Kazuo Kobayashi, Kei Takeshita, Takuya Hashimoto, Moritsugu Kimura, Yoshimi Muta, Hisashi Yokomizo, Yuichi Takashi, Shunichiro Tsukamoto, Kouichi Tamura et al. · 2025 · Journal of Diabetes Investigation
  42. Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis
    Shiwen Yang, Qiaozhi Hu, Kexin Liu, Binjie Xiao, Bofei Zhang, Na Su · 2025 · Frontiers in Pharmacology
  43. Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey
    Chandan Das, Debasmita Tripathy, Surendranath Swain, Navin Sudhakaran, Kanishka Uthansingh, Pradeep Mallick, Girish Kumar Pati · 2021 · Cureus
  44. An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
    Ping Wu, Zhenyu Liu, Xiaohong Jiang, Hao Fang · 2019 · Current Drug Targets
  45. New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis
    Sanja Stojsavljević, Marko Duvnjak, Lucija Virović-Jukić, Davor Hrabar, Lea Smircic Duvnjak · 2020 · Journal of Clinical and Translational Hepatology
  46. Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy
    Juan P. Frías, Jill Maaske, Lisa J. Suchower, Lars Johansson, Paul D. Hockings, Nayyar Iqbal, John P.H. Wilding · 2021 · Diabetes Obesity and Metabolism
  47. Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide ‐1 receptor agonists: A narrative review and proposed clinical approach
    Meir Schechter, Matan Fischer, Ofri Mosenzon · 2022 · Diabetes Obesity and Metabolism
  48. Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models
    Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee · 2023 · Biomedicine & Pharmacotherapy
  49. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients With Type 2 Diabetes: A Chart-Based Analysis
    Hisayuki Katsuyama, Mariko Hakoshima, Takehiro Iijima, Hiroki Adachi, Hidekatsu Yanai · 2020 · Journal of Endocrinology and Metabolism
  50. Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes
    Motonori Sato, Yoshifumi Tamura, Hideyoshi Kaga, Nozomu Yamasaki, Mai Kiya, Satoshi Kadowaki, Daisuke Sugimoto, Takashi Funayama, Yuki Someya, Saori Kakehi et al. · 2021 · Biomedicines
  51. Diabetes and Metabolic Dysfunction–associated Steatotic Liver Disease in Adults: A Clinical Practice Guideline
    James Kim, HARPREET SINGH BAJAJ, Alnoor S. Ramji, Chantal Bémeur, Giada Sebastiani · 2025 · Canadian Journal of Diabetes
  52. Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
    Virginia Bellido, Julia Martínez, F. L. Calvo, Aída Villarroel, Edurne Lecumberri, Juan Moreno, Carlos Morillas, Silvia Rodrigo, Aitziber Izarra, Albert Lecube · 2022 · Diabetes Therapy
  53. Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice
    Angelo Di Vincenzo, Marika Crescenzi, Marnie Granzotto, Marco Vecchiato, Paola Fioretto, Roberto Vettor, Marco Rossato · 2024 · Journal of Endocrinological Investigation
  54. Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome
    Stewart Gary Albert, Emily M. Wood · 2021 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  55. The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Takeshi Goya, Koji Imoto, Shigeki Tashiro, Tomomi Aoyagi, Motoi Takahashi, Miho Kurokawa, Hideo Suzuki, Masatake Tanaka, Masaki Kato, Motoyuki Kohjima et al. · 2022 · Gastroenterology Insights
  56. Retrospective analysis (2009–2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India
    Nithyanantham Kamal Raj, Madhanagopal Sathishkumar, Mani Arun Vignesh, Viswanathan Baskar, Saravanan Jebarani, Anandakumar Amutha, Mohan Deepa, Coimbatore Subramanyam Shanthi Rani, Sundaramoorthy Chandru, Ranjit Unnikrishnan I et al. · 2021 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  57. State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
    Yongin Cho, Yong‐ho Lee · 2022 · Endocrinology and Metabolism
  58. Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
    Emmanouil Koullias, John S. Koskinas · 2022 · Journal of Clinical and Translational Hepatology
  59. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
    Eun‐Jung Rhee · 2022 · Endocrinology and Metabolism
  60. Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis
    Fu‐Shun Yen, Ming‐Chih Hou, James Cheng‐Chung Wei, Yuhan Huang, Ying‐Hsiu Shih, Chun‐Wei Pan, Sing-Ting Wang, Chii‐Min Hwu, Chih‐Cheng Hsu · 2025 · Diabetes/Metabolism Research and Reviews
  61. Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm
    Alfredo Caturano, Davide Nilo, Giovanni Di Lorenzo, Maria Paola Rocco, Giuseppina Tagliaferri, Alessia Piacevole, Mariarosaria Donnarumma, Ilaria Iadicicco, Simona Maria Moretto, Carlo Acierno et al. · 2025 · Reviews in Cardiovascular Medicine
  62. Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study
    Jinyoung Kim, Kyungdo Han, Bongsung Kim, Ki‐Hyun Baek, Ki‐Ho Song, Mee Kyoung Kim, Hyuk‐Sang Kwon · 2022 · Diabetes Research and Clinical Practice
  63. Current Treatment Options, Including Diet, Exercise, and Medications
    Mazen Noureddin, Manal F. Abdelmalek · 2023 · Clinics in Liver Disease
  64. Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease
    Xiao Chen, Chang Xu, Ke Hu, Yang Yang, Yi-Jia Zhang, Hao-Zhe Shi, Qian Gu, Su‐Mei He, Cun Zhang, Dongdong Wang · 2023 · Expert Review of Clinical Pharmacology
  65. Role of Omega-3 Polyunsaturated Fatty Acid Supplementation in Patients with Type 2 Diabetes Mellitus
    Rehab H. Werida, Alaa Ramzy, Yousry Ebrahim, Maged W. Helmy · 2023 · Journal of Advanced Medical and Pharmaceutical Research
  66. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
    Angeliki Katsarou, Georgios Tsioulos, Eva N. Kassi, Antonios Chatzigeorgiou · 2024 · HORMONES
  67. Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
    Han Ah Lee, Hye Ah Lee, Hwi Young Kim · 2024 · Scientific Reports
  68. Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis
    Hua Duan, Fangyuan Chen · 2025 · Medicine
  69. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials
    Abdulrahman I. Alfayez, Jawaher M. Alfallaj, Mugahid A. Mobark, Abdullah Abdulaziz Alalwan, Osamah M. Alfayez · 2023 · Current Diabetes Reviews
  70. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Choungwon Jung, Soyoung Park, Hyunah Kim · 2023 · PLoS ONE
  71. Comparative efficacy of sodium-glucose transporter 2 inhibitors on lipid profiles in nonalcoholic fatty liver disease (NAFLD): a comprehensive Bayesian network meta-analysis
    Ibrahim Khalil, Md. Imran Hossain, Mahmuda Akter, Sajjad Ghanim Al‐Badri · 2025 · Annals of Medicine and Surgery
  72. Diabetes and the liver
    Ebo Dadey, TY Lim, Janine Makaronidis · 2025 · Clinical Medicine
  73. The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review
    Mihaela Simona Popoviciu, Lorena Păduraru, Mominur Rahman, Fatema Akter Supti, Roxana Adriana Stoica, Delia Reurean‐Pintilei, Cristina Ioana Bica, Simona Daniela Cavalu · 2024 · Journal of Mind and Medical Sciences
  74. The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease
    Na Ao, Jian Du, Shi Jin, Linna Suo, Jing Yang · 2024 · Diabetes Obesity and Metabolism
  75. Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options
    Emmanouil Koullias, Maria Papavdi, John S. Koskinas, Melanie J. Deutsch, Anastasia C. Thanopoulou · 2025 · Cureus
  76. Effects of sodium-glucose cotransporter-2 inhibitors on serum urate levels and gout in patients with and without type 2 diabetes: a systematic review and network meta-analysis
    Qiaozhi Hu, Shiwen Yang, Bofei Zhang, Na Su · 2025 · International Journal of Clinical Pharmacy
  77. Effects of Dapagliflozin on Adipose and Liver Fatty Acid Composition and mRNA Expression Involved in Lipid Metabolism in High-Fat-Fed Rats
    Daisuke Sato, Takao Nakamura, Jota Amarume, Mizuna Yano, Yuta Umehara, Atsuyoshi Nishina, Kazuhiko Tsutsumi, Zhonggang Feng, Masataka Kusunoki · 2022 · Endocrine Metabolic & Immune Disorders - Drug Targets
  78. Implementation of Cardiometabolic Centers and Training Programs
    Mohamad Badie Taha, Neha Rao, Muthiah Vaduganathan, Miguel Cainzos‐Achirica, Khurram Nasir, Kershaw V. Patel · 2022 · Current Diabetes Reports
  79. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease
    Jose Arriola‐Montenegro, Renato Beas, Renato Cerna-Viacava, Andres Chapoñan-Lavalle, Karla Hernandez Randich, Diego Chambergo‐Michilot, Herson Flores Sanga, Pornthira Mutirangura · 2023 · World Journal of Cardiology
  80. Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors
    Grzegorz Procyk, Jakub Jaworski, Aleksandra Gąsecka, Krzysztof Jerzy Filipiak, Josip A. Borovac · 2024 · Advances in Medical Sciences
  81. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis
    Yizhou Huang, Gangyi Yang, Cong Wang, Xingyu Chen, Lili Zhang · 2021 · World Journal of Diabetes
  82. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Eliza Mankieva, Кухарева Елена Ивановна · 2023 · Russian Journal of Evidence-Based Gastroenterology
  83. The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Silvia Pieralice, Rocco Amendolara, Valentina Berna, Giuseppina Manganaro, Annalisa Zurru, Luca D’Onofrio, Renata Risi, Marianna Alfonsi, Ernesto Maddaloni, Raffaella Buzzetti · 2025 · Diabetes Metabolic Syndrome and Obesity
  84. Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives
    Manisha C. Yadav, Smriti Verma, Purnima Tiwari, Madhav Nilakanth Mugale · 2024 · Life Sciences
  85. Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
    Anoushka Shenoy, Aijaz Ahmed, Donghee Kim · 2025 · Metabolism and Target Organ Damage
  86. Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus
    Emmanouil Koullias, Maria Papavdi, Stavros Athanasopoulos, Asimina Mitrakou, Melanie J. Deutsch, Pavlos Spyridon Zoumpoulis, Emmanuel K. Manesis, Anastasia C. Thanopoulou, John S. Koskinas · 2024 · Cureus
  87. Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
    V. Rajan, Ambarish Das, Venkatachalam Jayaseelan, K. K. Lohani, Chandrakant Lahariya · 2025 · Preventive Medicine Research & Reviews
  88. Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus
    Mohammed Ali Gameil, Mohammed Abdelgawad, Monir Bahgat, Ahmed Hassan El-Sebaie, Rehab Elsayed Marzouk · 2020 · The Egyptian Journal of Internal Medicine
  89. Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study
    Oscar Hou In Chou, Jing Ning, Raymond Ngai Chiu Chan, Cheuk To Chung, Helen Ye Rim Huang, Kenrick Ng, Edward Christopher Dee, Sharen Lee, Apichat Kaewdech, Tong Liu et al. · 2022 · medRxiv
  90. Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis
    Zhile Xiao, Xiao‐Nan Li, Jiahong Gong, Feng Zhou · 2025 · European journal of medical research
  91. Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends
    George Sarin Zacharia, Muhammad H Ashraf, Franklin Sosa, Anu Jacob, Harish Patel · 2025 · World Journal of Gastrointestinal Pharmacology and Therapeutics
  92. Evaluating the Comparative Effectiveness of Sodium-Glucose Transporter 2 Inhibitors (SGLT-2i) on Liver Enzymes in Patients With Nonalcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials
    Ibrahim Khalil, Md Imran Hossain, Mahmuda Akter · 2025 · AACE Endocrinology and Diabetes
  93. Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
    Konstantinos Stefanakis, Paschalis Karakasis, Dimitra Vasdeki, Djordje S. Popovic, Dimitrios Patoulias, Manfredi Rizzo, Christos Socrates Mantzoros · 2026 · Endocrine Reviews
  94. Dapagliflozin treatment decreases visceral and subcutaneous adipose tissue: a systematic review and meta-analysis
    Carlos U. Vargas-Ramírez, Víctor Posadas-Posadas, Renata Ochoa-Précoma, Leonardo M. Porchia, Ricardo Pérez-Fuentes, M. Elba González-Mejía · 2024 · Diabetology International
  95. Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review
    Rachelle Choi, Jatin P. Vemuri, Alekya Poloju, Rishi Raj, Anurag Mehta, Amon Asgharpour, Mohammad Shadab Siddiqui, Priyanka Majety · 2025 · Endocrines
  96. Efficacy of sodium-glucose co-transporter 2 inhibitors in treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Syeda Hoorulain Ahmed, Abdul Moeed, Eisha Waqar, Sahar Rizwan, Nimra Hasnain, Mohammad Aadil Qamar, Kaneez Fatima, Abdul Mannan Khan Minhas · 2022 · Obesity Medicine
  97. Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment
    Abdelilah Arredouani · 2022 · IntechOpen eBooks
  98. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
    Iryna Oleksandrivna Kostitska, Nadia Protas, Liliia Petrovska · 2023 · Diabetes Obesity Metabolic Syndrome
  99. Effect of bariatric endoscopy on liver fibrosis and steatosis and the course of NAFLD – a prospective interventional study
    Adam Vašura, Evžen Machytka, Ondřej Urban, Jitka Macháčková, Lubomír Pavliska, Zdeněk Berka, Zdeněk Švagera, Marek Bužga · 2024 · Annals of Hepatology
  100. Realisation of Remission of Diabetes Using Pharmacotherapy (DiaRem-1)
    Anand Sudhayakumar, Durairaj Arjunan, Shobhit Bhansali, Harish Bhujade, Sanjay Kumar Bhadada, Sunita Malhotra, Rama Walia · 2025 · Indian Journal of Endocrinology and Metabolism